Novo Modelo de Mucosite Intestinal Induzida pela AssociaÃÃo de Irinotecano e 5-Fluorouracil em Camundongos C57BL/6

Detalhes bibliográficos
Autor(a) principal: VenÃcia Bruna MagalhÃes Pereira
Data de Publicação: 2013
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Biblioteca Digital de Teses e Dissertações da UFC
Texto Completo: http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=11712
Resumo: Introduction: Intestinal mucositis is a common side effect of anticancer regimens for first-line treatment of colorectal cancer. Among such drugs are irinotecan and 5-FU used in combination. Many studies have been conducted on the pathogenesis of MI. However, further investigations are necessary, because the course of MI may vary according to the drug regimen and employees. Then aimed to develop a new experimental model of MI induced by the combination of IRI and 5-FU in mice. Methods and Results: C57BL/6 mice (20-25g, n=6) were injected with saline (100ÂL, i.p), IRI (30 or 45 mg/kg, i.p), 5-FU (25, 37.5 or 50 mg/kg, i.p) or IRI+5-FU for 4 days. On day 7, diarrhea, weight loss, and blood leukocyte count were registered. Following animal euthanasia, ileum samples were collected for histopathological analysis, myeloperoxidase activity (MPO, neutrophil/mg protein), TNF-&#945; and IL-6 levels (pg/mg tissue). Kaplan-Mayer log rank test, Kruskal Wallis/Dunnâs or ANOVA/Bonferroniâs test was used for statistical analysis. p<0.05 was accepted. The best dose combination able to induce IM with no important mortality on day 7 was 5-FU (37.5 mg/kg) +IRI (45 mg/kg) (0% mortality), which was then used for subsequent studies. IRI+5-FU induced (p<0.001) diarrhea (2[0-3]), weight loss (86.7Â3.9g), and leukopenia (7.3Â 2.3 x103) versus saline group (0[0-1]; 101.1Â0.6; 215.5Â 54.1, respectively) or each drug given alone (5-FU: diarrhea (0[0-1]), weight loss [92.6Â2.7], and leukopenia [30.4Â 13.4]; IRI: diarrhea (0[0-1]), weight loss [94.8Â2.1], and leukopenia [49.2Â 5.5]). In addition, IRI+5-FU induced inflammatory cells infiltration, and loss of villi and crypt architecture (4[3-4]), increased in MPO activity (14641Â1598 neutrophil/mgproteÃn), TNF-a (3.2Â0.9 pg/mg tissue), IL-6 (1.4Â0.5 pg/mg tissue) tissue levels versus saline-injected group (0[0-1], 5747Â1155; 0.7Â0.2; 0.3Â0.1) or the drugs injected alone (5-FU: Intestinal damage (2.5[2-3]), MPO [3788Â1212], TNF-&#945; [0.7Â0.2], IL-6 [0.2Â2.3]; IRI: Intestinal damage (1[0-2]), MPO [3580Â1613], TNF-&#945; [0.4Â0,2], IL-6 [0.07Â0.05]) (p<0.05). Conclusion: We developed a new experimental model of IM induced by the combination of IRI+5-FU in mice, which opens perspective for a more appropriate knowledge concerning the pathogenesis of IM.
id UFC_d5f241be3c3f0db77e6f37ec2f8b3f3f
oai_identifier_str oai:www.teses.ufc.br:8020
network_acronym_str UFC
network_name_str Biblioteca Digital de Teses e Dissertações da UFC
spelling info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisNovo Modelo de Mucosite Intestinal Induzida pela AssociaÃÃo de Irinotecano e 5-Fluorouracil em Camundongos C57BL/62013-12-05Roberto CÃsar Pereira Lima JÃnior87277123387http://lattes.cnpq.br/8104904120076956Pedro Jorge Caldas MagalhÃes38546620334http://lattes.cnpq.br/0057645238802910Luzia Kalyne Almeida Moreira Leal38259850320http://lattes.cnpq.br/344772815322501601801911363http://lattes.cnpq.br/9284843601128833VenÃcia Bruna MagalhÃes PereiraUniversidade Federal do CearÃPrograma de PÃs-GraduaÃÃo em FarmacologiaUFCBRInflammationMucositisFluorouracilFARMACOLOGIAIntroduction: Intestinal mucositis is a common side effect of anticancer regimens for first-line treatment of colorectal cancer. Among such drugs are irinotecan and 5-FU used in combination. Many studies have been conducted on the pathogenesis of MI. However, further investigations are necessary, because the course of MI may vary according to the drug regimen and employees. Then aimed to develop a new experimental model of MI induced by the combination of IRI and 5-FU in mice. Methods and Results: C57BL/6 mice (20-25g, n=6) were injected with saline (100ÂL, i.p), IRI (30 or 45 mg/kg, i.p), 5-FU (25, 37.5 or 50 mg/kg, i.p) or IRI+5-FU for 4 days. On day 7, diarrhea, weight loss, and blood leukocyte count were registered. Following animal euthanasia, ileum samples were collected for histopathological analysis, myeloperoxidase activity (MPO, neutrophil/mg protein), TNF-&#945; and IL-6 levels (pg/mg tissue). Kaplan-Mayer log rank test, Kruskal Wallis/Dunnâs or ANOVA/Bonferroniâs test was used for statistical analysis. p<0.05 was accepted. The best dose combination able to induce IM with no important mortality on day 7 was 5-FU (37.5 mg/kg) +IRI (45 mg/kg) (0% mortality), which was then used for subsequent studies. IRI+5-FU induced (p<0.001) diarrhea (2[0-3]), weight loss (86.7Â3.9g), and leukopenia (7.3 2.3 x103) versus saline group (0[0-1]; 101.1Â0.6; 215.5 54.1, respectively) or each drug given alone (5-FU: diarrhea (0[0-1]), weight loss [92.6Â2.7], and leukopenia [30.4 13.4]; IRI: diarrhea (0[0-1]), weight loss [94.8Â2.1], and leukopenia [49.2 5.5]). In addition, IRI+5-FU induced inflammatory cells infiltration, and loss of villi and crypt architecture (4[3-4]), increased in MPO activity (14641Â1598 neutrophil/mgproteÃn), TNF-a (3.2Â0.9 pg/mg tissue), IL-6 (1.4Â0.5 pg/mg tissue) tissue levels versus saline-injected group (0[0-1], 5747Â1155; 0.7Â0.2; 0.3Â0.1) or the drugs injected alone (5-FU: Intestinal damage (2.5[2-3]), MPO [3788Â1212], TNF-&#945; [0.7Â0.2], IL-6 [0.2Â2.3]; IRI: Intestinal damage (1[0-2]), MPO [3580Â1613], TNF-&#945; [0.4Â0,2], IL-6 [0.07Â0.05]) (p<0.05). Conclusion: We developed a new experimental model of IM induced by the combination of IRI+5-FU in mice, which opens perspective for a more appropriate knowledge concerning the pathogenesis of IM.IntroduÃÃo: Mucosite intestinal à um efeito adverso comum dos regimes anticÃncer de primeira linha para o tratamento do cÃncer colorretal. Dentre esses fÃrmacos estÃo o irinotecano e 5-FU utilizados em associaÃÃo. Muitos estudos tÃm sido realizados sobre a patogÃnese da MI. No entanto, novas investigaÃÃes sÃo necessarias, pois o curso da MI pode variar de acordo com o fÃrmaco e regime empregados. Objetivou-se entÃo desenvolver um novo modelo experimental de MI induzida pela combinaÃÃo de IRI e 5-FU em camundogos. MÃtodos e Resultados: camundongos C57BL/6 (20-25g, n=6) foram injetados com salina (100ÂL, i.p), IRI (30 ou 45 mg/kg, i.p), 5-FU (25, 37,5 ou 50 mg/kg, i.p) ou IRI+5-FU em doses combinadas por 4 dias. No 7 dia, diarreia, perda de peso e contagem de leucÃcitos foram registradas. ApÃs a eutanÃsia dos animais, amostras do Ãleo foram coletadas para anÃlise histopatolÃgica, atividade de mieloperoxidase (neutrÃfilo/mg proteÃna), nÃveis de TNF-&#945; e IL-6 (pg/mg tecido). Teste Kaplan-Mayer log rank, Kruskal Wallis/Dunnâs ou teste ANOVA/Bonferroni foram usados para analise estatistica. p<0,05 foi aceito como significativo. A melhor combinaÃÃo de dose para induzir a MI sem mortalidade importante no 7 dia foi 5-FU (37,5 mg/kg) + IRI (45 mg/kg) (0% mortalidade), que foi entÃo usada para estudos subsequentes. IRI+5-FU induziu (p<0,001) diarreia (2[0-3]), perda de peso (86,7Â3,9g), e leucopenia (7,3 2,3x103) versus grupo salina (0[0-1]; 101,1Â0,6; 215,5 54,1, respectivamente) ou cada droga dada sozinha (5-FU: diarreia (0[0-1]), perda de peso [92,6Â2,7], e leucopenia [30,4 13,4]; IRI: diarreia (0[0-1]), perda de peso [94,8Â2,1], e leucopenia [49,2 5,5]). Adicionalmente, IRI+5-FU induziu infiltrado de cÃlulas inflamatÃrias, perda de vilos e arquitetura das criptas (4[4-4]), aumento na atividade de MPO (14641Â1598 neutrÃfilo/mgproteÃna), TNF-a (3,2Â0,9 pg/mg de tecido), IL-6 (1,4Â0,5 pg/mg de tecido) nÃveis teciduais versus grupo injetado com salina (0[0-1], 5747Â1155; 0,7Â0,2; 0,3Â0,1) ou com fÃrmacos injetados isoladamente (5-FU: dano intestinal (2.5[2-3]), MPO [3788Â1212], TNF-&#945; [0,7Â0,2], IL-6 [0,2Â2,3]; IRI: dano intestinal (1[0-2]), MPO [3580Â1613], TNF-&#945; [0,4Â0,2], IL-6 [0,07Â0,05]) (p<0,05). ConclusÃo: Desenvolvemos um novo modelo experimental de MI induzida pela combinaÃÃo de IRI+5-FU em camundongos, que abre perspectiva para um maior conhecimento sobre a patogÃnese da MI.Conselho Nacional de Desenvolvimento CientÃfico e TecnolÃgicohttp://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=11712application/pdfinfo:eu-repo/semantics/openAccessporreponame:Biblioteca Digital de Teses e Dissertações da UFCinstname:Universidade Federal do Cearáinstacron:UFC2019-01-21T11:24:54Zmail@mail.com -
dc.title.pt.fl_str_mv Novo Modelo de Mucosite Intestinal Induzida pela AssociaÃÃo de Irinotecano e 5-Fluorouracil em Camundongos C57BL/6
title Novo Modelo de Mucosite Intestinal Induzida pela AssociaÃÃo de Irinotecano e 5-Fluorouracil em Camundongos C57BL/6
spellingShingle Novo Modelo de Mucosite Intestinal Induzida pela AssociaÃÃo de Irinotecano e 5-Fluorouracil em Camundongos C57BL/6
VenÃcia Bruna MagalhÃes Pereira
Inflammation
Mucositis
Fluorouracil
FARMACOLOGIA
title_short Novo Modelo de Mucosite Intestinal Induzida pela AssociaÃÃo de Irinotecano e 5-Fluorouracil em Camundongos C57BL/6
title_full Novo Modelo de Mucosite Intestinal Induzida pela AssociaÃÃo de Irinotecano e 5-Fluorouracil em Camundongos C57BL/6
title_fullStr Novo Modelo de Mucosite Intestinal Induzida pela AssociaÃÃo de Irinotecano e 5-Fluorouracil em Camundongos C57BL/6
title_full_unstemmed Novo Modelo de Mucosite Intestinal Induzida pela AssociaÃÃo de Irinotecano e 5-Fluorouracil em Camundongos C57BL/6
title_sort Novo Modelo de Mucosite Intestinal Induzida pela AssociaÃÃo de Irinotecano e 5-Fluorouracil em Camundongos C57BL/6
author VenÃcia Bruna MagalhÃes Pereira
author_facet VenÃcia Bruna MagalhÃes Pereira
author_role author
dc.contributor.advisor1.fl_str_mv Roberto CÃsar Pereira Lima JÃnior
dc.contributor.advisor1ID.fl_str_mv 87277123387
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/8104904120076956
dc.contributor.referee1.fl_str_mv Pedro Jorge Caldas MagalhÃes
dc.contributor.referee1ID.fl_str_mv 38546620334
dc.contributor.referee1Lattes.fl_str_mv http://lattes.cnpq.br/0057645238802910
dc.contributor.referee2.fl_str_mv Luzia Kalyne Almeida Moreira Leal
dc.contributor.referee2ID.fl_str_mv 38259850320
dc.contributor.referee2Lattes.fl_str_mv http://lattes.cnpq.br/3447728153225016
dc.contributor.authorID.fl_str_mv 01801911363
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/9284843601128833
dc.contributor.author.fl_str_mv VenÃcia Bruna MagalhÃes Pereira
contributor_str_mv Roberto CÃsar Pereira Lima JÃnior
Pedro Jorge Caldas MagalhÃes
Luzia Kalyne Almeida Moreira Leal
dc.subject.eng.fl_str_mv Inflammation
Mucositis
Fluorouracil
topic Inflammation
Mucositis
Fluorouracil
FARMACOLOGIA
dc.subject.cnpq.fl_str_mv FARMACOLOGIA
dc.description.sponsorship.fl_txt_mv Conselho Nacional de Desenvolvimento CientÃfico e TecnolÃgico
dc.description.abstract..fl_txt_mv Introduction: Intestinal mucositis is a common side effect of anticancer regimens for first-line treatment of colorectal cancer. Among such drugs are irinotecan and 5-FU used in combination. Many studies have been conducted on the pathogenesis of MI. However, further investigations are necessary, because the course of MI may vary according to the drug regimen and employees. Then aimed to develop a new experimental model of MI induced by the combination of IRI and 5-FU in mice. Methods and Results: C57BL/6 mice (20-25g, n=6) were injected with saline (100ÂL, i.p), IRI (30 or 45 mg/kg, i.p), 5-FU (25, 37.5 or 50 mg/kg, i.p) or IRI+5-FU for 4 days. On day 7, diarrhea, weight loss, and blood leukocyte count were registered. Following animal euthanasia, ileum samples were collected for histopathological analysis, myeloperoxidase activity (MPO, neutrophil/mg protein), TNF-&#945; and IL-6 levels (pg/mg tissue). Kaplan-Mayer log rank test, Kruskal Wallis/Dunnâs or ANOVA/Bonferroniâs test was used for statistical analysis. p<0.05 was accepted. The best dose combination able to induce IM with no important mortality on day 7 was 5-FU (37.5 mg/kg) +IRI (45 mg/kg) (0% mortality), which was then used for subsequent studies. IRI+5-FU induced (p<0.001) diarrhea (2[0-3]), weight loss (86.7Â3.9g), and leukopenia (7.3Â 2.3 x103) versus saline group (0[0-1]; 101.1Â0.6; 215.5Â 54.1, respectively) or each drug given alone (5-FU: diarrhea (0[0-1]), weight loss [92.6Â2.7], and leukopenia [30.4Â 13.4]; IRI: diarrhea (0[0-1]), weight loss [94.8Â2.1], and leukopenia [49.2Â 5.5]). In addition, IRI+5-FU induced inflammatory cells infiltration, and loss of villi and crypt architecture (4[3-4]), increased in MPO activity (14641Â1598 neutrophil/mgproteÃn), TNF-a (3.2Â0.9 pg/mg tissue), IL-6 (1.4Â0.5 pg/mg tissue) tissue levels versus saline-injected group (0[0-1], 5747Â1155; 0.7Â0.2; 0.3Â0.1) or the drugs injected alone (5-FU: Intestinal damage (2.5[2-3]), MPO [3788Â1212], TNF-&#945; [0.7Â0.2], IL-6 [0.2Â2.3]; IRI: Intestinal damage (1[0-2]), MPO [3580Â1613], TNF-&#945; [0.4Â0,2], IL-6 [0.07Â0.05]) (p<0.05). Conclusion: We developed a new experimental model of IM induced by the combination of IRI+5-FU in mice, which opens perspective for a more appropriate knowledge concerning the pathogenesis of IM.
dc.description.abstract.por.fl_txt_mv IntroduÃÃo: Mucosite intestinal à um efeito adverso comum dos regimes anticÃncer de primeira linha para o tratamento do cÃncer colorretal. Dentre esses fÃrmacos estÃo o irinotecano e 5-FU utilizados em associaÃÃo. Muitos estudos tÃm sido realizados sobre a patogÃnese da MI. No entanto, novas investigaÃÃes sÃo necessarias, pois o curso da MI pode variar de acordo com o fÃrmaco e regime empregados. Objetivou-se entÃo desenvolver um novo modelo experimental de MI induzida pela combinaÃÃo de IRI e 5-FU em camundogos. MÃtodos e Resultados: camundongos C57BL/6 (20-25g, n=6) foram injetados com salina (100ÂL, i.p), IRI (30 ou 45 mg/kg, i.p), 5-FU (25, 37,5 ou 50 mg/kg, i.p) ou IRI+5-FU em doses combinadas por 4 dias. No 7 dia, diarreia, perda de peso e contagem de leucÃcitos foram registradas. ApÃs a eutanÃsia dos animais, amostras do Ãleo foram coletadas para anÃlise histopatolÃgica, atividade de mieloperoxidase (neutrÃfilo/mg proteÃna), nÃveis de TNF-&#945; e IL-6 (pg/mg tecido). Teste Kaplan-Mayer log rank, Kruskal Wallis/Dunnâs ou teste ANOVA/Bonferroni foram usados para analise estatistica. p<0,05 foi aceito como significativo. A melhor combinaÃÃo de dose para induzir a MI sem mortalidade importante no 7 dia foi 5-FU (37,5 mg/kg) + IRI (45 mg/kg) (0% mortalidade), que foi entÃo usada para estudos subsequentes. IRI+5-FU induziu (p<0,001) diarreia (2[0-3]), perda de peso (86,7Â3,9g), e leucopenia (7,3 2,3x103) versus grupo salina (0[0-1]; 101,1Â0,6; 215,5 54,1, respectivamente) ou cada droga dada sozinha (5-FU: diarreia (0[0-1]), perda de peso [92,6Â2,7], e leucopenia [30,4 13,4]; IRI: diarreia (0[0-1]), perda de peso [94,8Â2,1], e leucopenia [49,2 5,5]). Adicionalmente, IRI+5-FU induziu infiltrado de cÃlulas inflamatÃrias, perda de vilos e arquitetura das criptas (4[4-4]), aumento na atividade de MPO (14641Â1598 neutrÃfilo/mgproteÃna), TNF-a (3,2Â0,9 pg/mg de tecido), IL-6 (1,4Â0,5 pg/mg de tecido) nÃveis teciduais versus grupo injetado com salina (0[0-1], 5747Â1155; 0,7Â0,2; 0,3Â0,1) ou com fÃrmacos injetados isoladamente (5-FU: dano intestinal (2.5[2-3]), MPO [3788Â1212], TNF-&#945; [0,7Â0,2], IL-6 [0,2Â2,3]; IRI: dano intestinal (1[0-2]), MPO [3580Â1613], TNF-&#945; [0,4Â0,2], IL-6 [0,07Â0,05]) (p<0,05). ConclusÃo: Desenvolvemos um novo modelo experimental de MI induzida pela combinaÃÃo de IRI+5-FU em camundongos, que abre perspectiva para um maior conhecimento sobre a patogÃnese da MI.
description Introduction: Intestinal mucositis is a common side effect of anticancer regimens for first-line treatment of colorectal cancer. Among such drugs are irinotecan and 5-FU used in combination. Many studies have been conducted on the pathogenesis of MI. However, further investigations are necessary, because the course of MI may vary according to the drug regimen and employees. Then aimed to develop a new experimental model of MI induced by the combination of IRI and 5-FU in mice. Methods and Results: C57BL/6 mice (20-25g, n=6) were injected with saline (100ÂL, i.p), IRI (30 or 45 mg/kg, i.p), 5-FU (25, 37.5 or 50 mg/kg, i.p) or IRI+5-FU for 4 days. On day 7, diarrhea, weight loss, and blood leukocyte count were registered. Following animal euthanasia, ileum samples were collected for histopathological analysis, myeloperoxidase activity (MPO, neutrophil/mg protein), TNF-&#945; and IL-6 levels (pg/mg tissue). Kaplan-Mayer log rank test, Kruskal Wallis/Dunnâs or ANOVA/Bonferroniâs test was used for statistical analysis. p<0.05 was accepted. The best dose combination able to induce IM with no important mortality on day 7 was 5-FU (37.5 mg/kg) +IRI (45 mg/kg) (0% mortality), which was then used for subsequent studies. IRI+5-FU induced (p<0.001) diarrhea (2[0-3]), weight loss (86.7Â3.9g), and leukopenia (7.3Â 2.3 x103) versus saline group (0[0-1]; 101.1Â0.6; 215.5Â 54.1, respectively) or each drug given alone (5-FU: diarrhea (0[0-1]), weight loss [92.6Â2.7], and leukopenia [30.4Â 13.4]; IRI: diarrhea (0[0-1]), weight loss [94.8Â2.1], and leukopenia [49.2Â 5.5]). In addition, IRI+5-FU induced inflammatory cells infiltration, and loss of villi and crypt architecture (4[3-4]), increased in MPO activity (14641Â1598 neutrophil/mgproteÃn), TNF-a (3.2Â0.9 pg/mg tissue), IL-6 (1.4Â0.5 pg/mg tissue) tissue levels versus saline-injected group (0[0-1], 5747Â1155; 0.7Â0.2; 0.3Â0.1) or the drugs injected alone (5-FU: Intestinal damage (2.5[2-3]), MPO [3788Â1212], TNF-&#945; [0.7Â0.2], IL-6 [0.2Â2.3]; IRI: Intestinal damage (1[0-2]), MPO [3580Â1613], TNF-&#945; [0.4Â0,2], IL-6 [0.07Â0.05]) (p<0.05). Conclusion: We developed a new experimental model of IM induced by the combination of IRI+5-FU in mice, which opens perspective for a more appropriate knowledge concerning the pathogenesis of IM.
publishDate 2013
dc.date.issued.fl_str_mv 2013-12-05
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
status_str publishedVersion
format masterThesis
dc.identifier.uri.fl_str_mv http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=11712
url http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=11712
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal do CearÃ
dc.publisher.program.fl_str_mv Programa de PÃs-GraduaÃÃo em Farmacologia
dc.publisher.initials.fl_str_mv UFC
dc.publisher.country.fl_str_mv BR
publisher.none.fl_str_mv Universidade Federal do CearÃ
dc.source.none.fl_str_mv reponame:Biblioteca Digital de Teses e Dissertações da UFC
instname:Universidade Federal do Ceará
instacron:UFC
reponame_str Biblioteca Digital de Teses e Dissertações da UFC
collection Biblioteca Digital de Teses e Dissertações da UFC
instname_str Universidade Federal do Ceará
instacron_str UFC
institution UFC
repository.name.fl_str_mv -
repository.mail.fl_str_mv mail@mail.com
_version_ 1643295187463569408